Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery

NCT01161641 | Terminated Phase 1

• 1 other identifier: PGX-ODSH-2009-PLE
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 4

Brief Summary

Protein Losing Enteropathy (PLE) is a serious medical condition that may develop in children and adults with congenital heart disease for which a palliative procedure known as the "Fontan procedure" has been performed. The loss of serum proteins into the gastrointestinal tract that is associated with PLE can cause serious symptoms and life-threatening complications. A number of clinical studies have suggested that heparin administration can have clinical benefit in children with PLE, however the risk of bleeding associated with the administration of heparin is an important concern and commonly limits its administration. ODSH is a desulfated heparin with minimal anticoagulation properties but which, in pre-clinical studies, appears to have the potential to replace heparin and greatly reduce the risk of bleeding. This open label study is to assess the safety and evidence of therapeutic effect of the administration of ODSH as a 4-day continuous intravenous infusion in patients with an exacerbation of their PLE.

Conditions

Protein Losing Enteropathy

Keywords

Protein Losing Enteropathy

Outcome Measures

Primary Outcomes (4)

• Clinical improvement of PLE symptoms and signs.

  Clinical Improvement of signs \& symptoms of PLE such as diarrhea, abdominal pain, peripheral edema, and ascites. Visual/categorical scales will be used by the study subjects and the investigators to assess diarrhea/abdominal pain intensity as well as The Global Impression of Improvement. The investigator will assess peripheral edema and ascites.

  Day 4 after 96 hours of IV continuous infusion of ODSH

• Fecal alpha 1 antitrypsin (FA1AT)

  Decrease of Fecal alpha 1 antitrypsin level at Day 4 compared to baseline.

  Day 4 after 96 hours of ODSH IV continuous infusion

• Serum albumin levels.

  Serum albumin levels at Day 4 compared to Baseline. A serum albumin level of 3 or more mg/dL or at least an increase of 25% from baseline at Day 4 or the reduction in the need for additional albumin infusions will be considered as clinically significant.

  Day 4 after 96 hours of continuous IV infusion of ODSH

• ODSH safety

  aPTT as a measure of coagulation effect from ODSH will be measured every day. If the aPTT value is 8 or more seconds higher than the upper limit of normal value of aPTT for the study site then the ODSH infusion rate will be decreased as recommended in the protocol. Coagulation and bleeding abnormalities will be monitored closely by the investigator. Liver enzymes will also be monitored during the study.

  Day 1, 2, 3 and 4

Secondary Outcomes (1)

• PK: ODSH plasma blood levels at steady state

  Day 3 (during Day 3 of ODSH IV continuous infusion)

Study Arms (3)

ODSH at 0.125 mg/kg/h

EXPERIMENTAL

First cohort of 3 subjects to be administered the lowest dose of ODSH.

Drug: ODSH at 0.125 mg/kg/h

ODSH at 0.250 mg/kg/h

EXPERIMENTAL

Second cohort of 3 subjects to receive the medium dose of ODSH

Drug: ODSH at 0.250 mg/kg/h

ODSH at 0.375 mg/kg/h

EXPERIMENTAL

Third and last cohort of subject to receive the high dose of ODSH.

Drug: ODSH at 0.375 mg/kg/h

Interventions

ODSH at 0.125 mg/kg/h DRUG

ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 1 of 0.125 mg/kg/h.

Also known as: Cohort 1

ODSH at 0.125 mg/kg/h

ODSH at 0.375 mg/kg/h DRUG

ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 3 of 0.375 mg/kg/h.

Also known as: Cohort 3

ODSH at 0.375 mg/kg/h

ODSH at 0.250 mg/kg/h DRUG

ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 2 of 0.250 mg/kg/h.

Also known as: Cohort 2

ODSH at 0.250 mg/kg/h

Eligibility Criteria

• Age: 6 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female ≥ 6 years old.
• History of single ventricle palliative surgery.
• Anticipated need for four or more days of hospitalization, in the investigator's judgment, for the treatment of exacerbation of PLE.
• Clinically significant PLE is defined as the presence of clinically significant symptoms (including, but not limited to, diarrhea, abdominal pain, peripheral edema and/or ascites), AND increased fecal alpha 1-antitrypsin (FA1AT; \> 200 mg/dl) OR hypoalbuminemia of \< 3 gr/dL; requiring supplemental albumin infusions.
• Prothrombin time (PT) and activated partial thromboplastin time (aPTT) not higher than 1.25 times the ULN for age.
• Platelet count of \> 80,000 per mm3, hemoglobin of \> 9.5 g/dL.
• The adult subject or the underage subject/legal guardian is willing to provide informed consent and to comply with the study procedures.
• Female subject of childbearing potential who is not pregnant, and is not lactating and is not planning to become pregnant during the study and will use medically acceptable contraception method for the duration of the study.

You may not qualify if:

• Has congenital or acquired hematologic disease or coagulation disorder.
• Has other type of PLE not associated with single ventricle palliative surgery e.g. subjects with congenital defects of glycation or with Crohn's disease; congenital trypsinogen or enterokinase deficiency;
• Has a clinical need for prophylactic or therapeutic treatment with oral or parenteral anticoagulant medications within 72 hours from the start of ODSH treatment or during the study. \[The use of antithrombotic agents such as acetyl salicylic acid for cardiovascular prophylaxis or clopidogrel (or similar drug class agents) is permitted\].
• Has documented liver failure or a serum ALT or AST greater than 1.5 times the upper limit of normal, or total bilirubin greater than 1.5 the upper limit of normal;
• Has clinically significant proteinuria or severe renal failure based on a creatinine clearance \< 30 mL/min calculated from plasma creatinine (Appendix B) with the Cockcroft-Gault formula for adults or with any of the recommended formulas for subjects 6 to 18 years old;
• Has active gastrointestinal ulcer disease or evidence of gastrointestinal bleeding or urinary tract bleeding or any other source of bleeding within 60 days of the Screening visit.
• History of HIV, hepatitis B or hepatitis C; and
• Major surgery, stroke or myocardial infarction within the past 60 days from screening. Subjects with recent minor surgery can be enrolled in the study.

Sponsors & Collaborators

• Jazz Pharmaceuticals: lead

Study Sites (4)

Children's Hospital Los Angeles ( Gastroenterology & Nutrition)

Los Angeles, California, 20027-6016, United States

Location

Department of Cardiology, Children's Hospital Boston

Boston, Massachusetts, 02115, United States

Location

Division of Pediatric Cardiology, University of Michigan Health System

Ann Arbor, Michigan, 48109-5204, United States

Location

Sanford Children's ( Sanford Research / USD)

Sioux Falls, South Dakota, 57104-4707, United States

Location

MeSH Terms

Conditions

Protein-Losing Enteropathies

Interventions

KPNA1 protein, human

Condition Hierarchy (Ancestors)

Intestinal Diseases; Gastrointestinal Diseases; Digestive System Diseases

Study Officials

• Mark Russell, MD

  Division of Pediatric Cardiology, University of Michigan Health System

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 9, 2010
• First Posted: July 13, 2010
• Study Start: July 1, 2010
• Primary Completion: February 1, 2012
• Study Completion: February 1, 2012
• Last Updated: December 2, 2021

Record last verified: 2015-08

Locations

US (4)